Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
MicroPort NeuroTech Limited (2172.HK)
Shanghai, CN
Established in 2004 and headquartered in Shanghai, People's Republic of China, MicroPort NeuroTech Limited is dedicated to the research, development, manufacturing, and global commercialization of neuro-interventional medical devices. The company's diverse product portfolio addresses various cerebrovascular conditions. For treating hemorrhagic stroke, it offers the NUMEN coil embolization system, the NUMEN FR coil detachment system, the Tubridge flow-diverting stent, the Willis intracranial stent graft system, and the Rebridge intracranial visualized stent. Additionally, MicroPort NeuroTech supplies the APOLLO intracranial arterial stent system for intracranial atherosclerotic disease, as well as the Bridge rapamycin target eluting vertebral artery stent system specifically designed for cerebral atherosclerotic stenosis. To address acute ischemic stroke, the company provides the Neurohawk stent thrombectomy device and the Tigertriever adjustable stent retriever.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.68% | +0.44% | -11.28% | -19.23% | -11.79% | -15.44% | -13.86% | -20.00% | -62.60% | -62.60% | -62.60% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+1.1% Q4'25: +9.7% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%-29.6% Q4'25: +14.7% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%+13.1% Q4'25: +45.6% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%+34.4% ★ Q4'25: +34.2% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%+26.6% ★ Q4'25: +53.7% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%-1.4% ★ Q4'25: -1.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.05× ★ Q4'25: 0.02× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
547.35M
est: 604.50M (-9.5%)
|
665.62M
est: 720.59M (-7.6%)
|
761.76M
est: 865.25M (-12.0%)
|
770.02M
est: 829.66M (-7.2%)
|
906.45M
906.45M – 906.45M
+9.3% YoY
|
1.05B
1.05B – 1.05B
+15.4% YoY
|
1.04B
1.04B – 1.04B
-1.0% YoY
|
| EBITDA |
175.46M
est: 204.59M (-14.2%)
|
221.60M
est: 435.98M (-49.2%)
|
340.48M
est: 523.50M (-35.0%)
|
339.00M
est: 501.97M (-32.5%)
|
548.43M
548.43M – 548.43M
+9.3% YoY
|
633.14M
633.14M – 633.14M
+15.4% YoY
|
626.58M
626.58M – 626.58M
-1.0% YoY
|
| EBIT |
133.28M
est: 161.82M (-17.6%)
|
165.51M
est: 373.05M (-55.6%)
|
299.84M
est: 447.95M (-33.1%)
|
264.98M
est: 429.52M (-38.3%)
|
469.28M
469.28M – 469.28M
+9.3% YoY
|
541.77M
541.77M – 541.77M
+15.4% YoY
|
536.15M
536.15M – 536.15M
-1.0% YoY
|
| Net Income |
-21.77M
est: 26.22M (-183.0%)
|
145.55M
est: 205.40M (-29.1%)
|
254.17M
est: 228.32M (+11.3%)
|
179.73M
est: 262.56M (-31.5%)
|
248.73M
248.73M – 248.73M
-5.3% YoY
|
284.26M
284.26M – 284.26M
+14.3% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
154.46M
est: 159.67M (-3.3%)
|
166.87M
est: 198.35M (-15.9%)
|
188.30M
est: 238.17M (-20.9%)
|
224.81M
est: 228.37M (-1.6%)
|
249.51M
249.51M – 249.51M
+9.3% YoY
|
288.05M
288.05M – 288.05M
+15.4% YoY
|
285.07M
285.07M – 285.07M
-1.0% YoY
|
| EPS |
-0.04
est: 0.05 (-193.0%)
|
0.25
est: 0.36 (-30.5%)
|
0.44
est: 0.40 (+10.0%)
|
0.31
est: 0.46 (-32.6%)
|
0.44
0.44 – 0.44
-5.3% YoY
|
0.50
0.50 – 0.50
+14.3% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI China Small-Cap ETF ECNS | 0.24% | 159.0K | 0.59% |
| 2 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.03% | 35.9K | 0.42% |
| 3 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.03% | 21.8K | 0.74% |
| 4 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.03% | 101.9K | 0.72% |
| 5 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.02% | 133.7K | 0.55% |
| 6 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.02% | 76.9K | 0.74% |
| 7 | WisdomTree Emerging Markets SmallCap Dividend UCITS ETF DGSD.L | 0.02% | 8.6K | 0.54% |
| 8 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.02% | 121.2K | 0.65% |
| 9 | WisdomTree Emerging Markets SmallCap Dividend Fund DGS | 0.02% | 288.6K | 0.58% |
| 10 | Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L | 0.01% | 16.8K | 0.35% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yiqun Wang | Senior Vice President & Executive Director | 2M | male |
| Zhiyong Xie | Chief Executive Officer, Executive Director & Chairman of MicroPort NeuroTech | 1M | male |
| Siu Lam Yeung | Company Secretary | — | female |
| Wangcai Liao | Chief Technology Officer | — | — |
| Lei Duan | Chief Marketing Officer and SVP of Sales & Promotion of Neurovascular Disease Treatment Solutions | — | male |
| Zaoli Wu | Manager of Human Resources & Administration | — | female |
| Zhuoping Hou | Senior Director of Finance | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2172.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
